MX2021010599A - Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares. - Google Patents

Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares.

Info

Publication number
MX2021010599A
MX2021010599A MX2021010599A MX2021010599A MX2021010599A MX 2021010599 A MX2021010599 A MX 2021010599A MX 2021010599 A MX2021010599 A MX 2021010599A MX 2021010599 A MX2021010599 A MX 2021010599A MX 2021010599 A MX2021010599 A MX 2021010599A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
disorders
ocular diseases
treating ocular
treating
Prior art date
Application number
MX2021010599A
Other languages
English (en)
Spanish (es)
Inventor
Sanjib Kumar Das
Cheng - Wen Lin
Original Assignee
Aerie Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerie Pharmaceuticals Inc filed Critical Aerie Pharmaceuticals Inc
Publication of MX2021010599A publication Critical patent/MX2021010599A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Biological Depolymerization Polymers (AREA)
MX2021010599A 2019-03-05 2020-03-05 Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares. MX2021010599A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814198P 2019-03-05 2019-03-05
PCT/US2020/021136 WO2020181060A1 (en) 2019-03-05 2020-03-05 Pharmaceutical compositions for treating ocular diseases or disorders

Publications (1)

Publication Number Publication Date
MX2021010599A true MX2021010599A (es) 2021-12-10

Family

ID=72337143

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021010599A MX2021010599A (es) 2019-03-05 2020-03-05 Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares.
MX2025002265A MX2025002265A (es) 2019-03-05 2021-09-02 Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025002265A MX2025002265A (es) 2019-03-05 2021-09-02 Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares

Country Status (9)

Country Link
US (2) US12478577B2 (cg-RX-API-DMAC7.html)
EP (1) EP3934646A4 (cg-RX-API-DMAC7.html)
JP (3) JP7570342B2 (cg-RX-API-DMAC7.html)
CN (3) CN118304422A (cg-RX-API-DMAC7.html)
AU (1) AU2020232314C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017436A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132635A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021010599A (cg-RX-API-DMAC7.html)
WO (1) WO2020181060A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3132635A1 (en) 2019-03-05 2020-09-10 Aerie Pharmaceuticals, Inc. Pharmaceutical compositions for treating ocular diseases or disorders
CN115066232B (zh) 2020-02-06 2024-12-10 视尔普斯眼科公司 用于治疗眼病的组合物和方法
CA3171563A1 (en) 2020-03-25 2021-09-30 Charles D. Blizzard Ocular implant containing a tyrosine kinase inhibitor
WO2021207486A1 (en) * 2020-04-08 2021-10-14 Aerie Pharmaceuticals, Inc. Treatments
BR112023022705A2 (pt) 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
US20240239750A1 (en) 2021-05-05 2024-07-18 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation
JP2026520094A (ja) 2023-04-11 2026-06-22 オキュラ セラピューティクス,インコーポレイテッド アキシチニブ多形ivを含む眼科インプラント
IL330178A (en) 2024-01-03 2026-08-01 LYOTROPIC DELIVERY SYSTEMS Ltd Topical formulations for delivering active ingredients to the back of the eye
AU2025217596A1 (en) 2024-02-05 2026-08-13 Sun Pharmaceutical Industries Limited Ophthalmic compositions of tyrosine kinase inhibitors and their uses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5445130B2 (ja) * 2006-05-02 2014-03-19 メディバス エルエルシー 眼の外部または内部への眼科用薬剤の送達法
WO2009130332A1 (en) 2008-04-25 2009-10-29 Dsm Ip Assets B.V. Particles comprising polymers with thioester bonds
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
CN107656332B (zh) * 2010-06-22 2021-10-15 东洋纺株式会社 液晶显示装置、偏振板及偏振片保护膜
BR112013018739A2 (pt) * 2010-12-29 2019-09-24 Jade Therapeutics Inc sistema de distribuição de medicamento ocular
US20140179802A1 (en) * 2011-05-02 2014-06-26 Dsm Ip Assets B.V. Fiber comprising a biodegradable polymer
WO2012150255A1 (en) * 2011-05-02 2012-11-08 Dsm Ip Assets B.V. Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology
HK1205461A1 (zh) * 2012-02-22 2015-12-18 Trustees Of Tufts College 用於眼部传输治疗剂的组合物和方法
WO2014053542A1 (en) 2012-10-02 2014-04-10 Dsm Ip Assets B.V. Drug delivery composition comprising proteins and biodegradable polyesteramides
JP6303199B2 (ja) 2012-10-24 2018-04-04 ディーエスエム アイピー アセッツ ビー.ブイ. 薬物送達のためのポリエステルアミドコポリマーを含む繊維
EP2956096A1 (en) * 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
WO2014165308A2 (en) 2013-04-01 2014-10-09 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
WO2015126477A1 (en) 2013-11-08 2015-08-27 Tyrx, Inc. Polymeric drug delivery system for treating surgical complications
US20160296627A1 (en) * 2013-12-06 2016-10-13 Envisia Therapeutics Inc. Intracameral implant for treatment of an ocular condition
EP3082761A2 (en) * 2013-12-20 2016-10-26 Emory University Formulations and methods for targeted ocular delivery of therapeutic agents
US9931306B2 (en) 2014-09-06 2018-04-03 Integral Biosystems Llc Methods and biocompatible compositions to achieve sustained drug release in the eye
CA2969171C (en) * 2014-12-18 2023-12-12 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
CN115337254A (zh) 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
WO2017120600A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Compositions and methods of treating wet age-related macular degeneration
US20180117148A1 (en) * 2016-10-28 2018-05-03 Andrew J. Holman Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders
EP3570888A1 (en) * 2017-03-03 2019-11-27 MacRegen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
CA3132635A1 (en) 2019-03-05 2020-09-10 Aerie Pharmaceuticals, Inc. Pharmaceutical compositions for treating ocular diseases or disorders

Also Published As

Publication number Publication date
JP7838047B2 (ja) 2026-03-31
US12478577B2 (en) 2025-11-25
KR20210135560A (ko) 2021-11-15
AU2020232314A1 (en) 2021-09-30
JP7570342B2 (ja) 2024-10-21
CA3132635A1 (en) 2020-09-10
WO2020181060A1 (en) 2020-09-10
MX2025002265A (es) 2025-04-02
EP3934646A1 (en) 2022-01-12
JP2022523548A (ja) 2022-04-25
CN118286445A (zh) 2024-07-05
BR112021017436A2 (pt) 2021-11-16
EP3934646A4 (en) 2022-12-14
US20260034056A1 (en) 2026-02-05
AU2020232314B2 (en) 2023-10-12
US20200306182A1 (en) 2020-10-01
JP7852008B2 (ja) 2026-04-27
JP2025004160A (ja) 2025-01-14
AU2020232314C1 (en) 2024-03-28
CN113784727B (zh) 2024-03-29
CN113784727A (zh) 2021-12-10
JP2025004161A (ja) 2025-01-14
CN118304422A (zh) 2024-07-09

Similar Documents

Publication Publication Date Title
MX2025002265A (es) Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares
WO2017177179A9 (en) Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
PH12023552741A1 (en) Psilocybin Compositions, Methods Of Making And Methods Of Using The Same
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
WO2019236775A8 (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
BRPI0520588B8 (pt) uso de composições farmacêuticas para o tratamento de doenças do ouvido interno
MX2025002953A (es) Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
GB2556500A (en) Compositions and methods for reducing visual loss
MX2020011817A (es) Metodos para tratar el linfoma.
WO2016100738A3 (en) Antifibrotic activity of gas6 inhibitor
MX2022012692A (es) Composiciones que comprenden nanoparticulas, metodo de elaboracion y usos de las mismas.
MX2023003993A (es) Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.
MX2022011576A (es) Moduladores de nlrp3.
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
WO2015048188A8 (en) Modified fibroblast growth factors for the treatment of ocular disorders
WO2020087057A8 (en) Macromolecular prodrug-based thermosensitive injectable gel as a novel drug delivery platform
MX2023005971A (es) Metodos y composicion para las modificaciones de kras.
WO2023009615A3 (en) Methods and compositions for treating or preventing neurological injury or neurological disorders
WO2020163493A3 (en) Materials and methods for treating a neurodegenerative disease
EA201790382A1 (ru) Способы лечения периимплантита
NZ804686A (en) Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors
MX2021005421A (es) Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos.
EP4487914A3 (en) Compositions and methods for treatment of homocystinuria